Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
Schizophrenia, Insulin Resistance
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Glucose Metabolism
Eligibility Criteria
Inclusion Criteria: Diagnosis of schizophrenia (any subtype) or schizoaffective disorder (any subtype) Treatment with clozapine for at least 1 year Stable dose of clozapine for at least 1 month Well established compliance with outpatient medications Female participants of non-childbearing potential or of childbearing potential and willing to practice appropriate birth control methods (complete abstinence from sexual intercourse, female sterilization, sterilization of male partner, implants of levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or double barrier methods of contraception using spermicide with either a condom or diaphragm) during the study Exclusion Criteria: Current substance abuse Psychiatrically unstable Significant medical illness, including severe cardiovascular, hepatic, or renal disease History of immunosuppression Current or recent radiation or chemotherapy treatment for cancer Chronic use of steroids Pregnant or breastfeeding
Sites / Locations
- Massachusetts General Hospital Schizophrenia Program
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Participants will take aripiprazole 15mg/day for 8 weeks.
Participants will take placebo for 8 weeks.